PharmaTalkRadio cover art

All Episodes

PharmaTalkRadio — 545 episodes

#
Title
1

Unlocking Unstructured Data with AI for Optimized Protocol Development

2

Bridging Access Gaps: Sponsor-Led Enablement of Research-Naïve Sites to Expand Patient Reach

3

Building Trust-Driven Partnerships: AstraZeneca’s Concierge Approach to Accelerating Site Activation and Enrollment

4

Eli Lilly on Site Enablement: Co-Designing Solutions with Sites

5

What a Strategic Partnership Looks Like in Practice: Inside the Takeda–Basil Collaboration That Delivered Tenfold Enrollment

6

Using Digital Technologies to Enhance Patient Experience and Better Manage Supply Chain

7

Ensuring Sustainability Throughout Drug and Device Development

8

Utilizing AI to Facilitate Combination Product Development

9

Achieving Effective Manufacturing Scaleup for Clinical and Commercial Success

10

Advances and Opportunities in Dual Chamber Injectables

11

How Evinova is Integrating AI into Clinical Development to Bring Big Impact to Big Pharma

12

How Bayer Reorganized Their Clinical Operations Structure for Efficiency and Cost Savings

13

How Amicus Embedded Patient Advocacy into its Corporate DNA

14

Designing Clinical Trials Balancing Simplicity with Complexity

15

Platform Approaches to Streamline Combination Product Development

16

What is the State of Clinical Trial Patient Matching Right Now?

17

Balancing Innovation and Practicality in Immuno-Oncology Dose Selection

18

Leveraging Local HCPs to Decentralize Clinical Research in North Carolina

19

Using Patient Engagement and Digital Innovation to Elevate Patient Insights and Outcomes

20

What to Expect at the 2026 Patients as Partners in Clinical Research Conference

21

The Role of the CMO in BD and M&A Partnering with Pharma

22

Advances in Payload Delivery and Drug Conjugation

23

Building Up a CMO Team as Your Company Evolves

24

Beyond LNPs: Delivering Genetic Medicines with Novel Vehicles

25

Pfizer on Advancing Data Analysis Capabilities through A New EDC/CDMS Platform

26

Insights from Tufts CSDD into Evolving Trial Partnerships Models

27

ADCs, Chemotherapy, and Checkpoint Blockade in Urothelial Carcinoma

28

Understanding the Immunological Effects of Radiopharmaceuticals

29

How J&J Is Integrating Patient Centricity Across the Enterprise

30

Biogen's Nicole Murphy on Drug Delivery Innovation and the Acquisition of Alcyone Therapeutics

31

What to Expect at the 2026 IO360° Summit

32

CMOs Working Flexibly with Consultants and Fractional Expertise

33

Principles and Strategies for Designing Best-in-Class Immuno-Oncology ADCs

34

How Patient Organizations are Bridging Patient Inclusivity Gaps at the Site-Level

35

How Roche Reduced Unnecessary Protocol Amendments to Impact Timeline and Cost

36

How to Embed Clinical Research in Rural and Frontier Health Systems

37

Optimizing the Value Proposition in Small Companies with Limited Budgets

38

From the DPHARM 2024 Archives: Biogen Pilot on Using Vocal Biomarkers to Identify Potential Participants for Clinical Trials

39

Merck on Enhancing Trial Participation, Relevance, and Impact through Patient and Community Engagement

40

Ensuring Continuity in Patient Insights to Strengthen Medicine Development

41

Accelerating Patient Enrollment in Clinical Trials by Deploying a Product Model Approach

42

Stanford's Dr Crystal Mackall on the Evolution of and Future Directions in Cell Therapy

43

De-Risking Clinical Operations by Taking a Scaffolding Approach to Outsourcing

44

Balancing Between Concentration and Volume when Developing Patient-Centric Biologics

45

Directors' Talk DPHARM 2025 - AI Sessions; Part III

46

Innovations in Manufacturing to Make CAR-T More Accessible and Affordable

47

Achieving Oral Delivery of Peptides through Formulation and Molecule Design Approaches

48

Catalyzing Change: The Business Imperative of Patient-Centric Drug Development

49

How Emerging Biopharma CMOs Can Better Partner with Patient Organizations

50

Joint Site and Sponsor Perspectives on Innovative Solutions Addressing Sites Challenges

51

What to Expect at the CRAACO: Clinical Research as a Care Option 2025 Event

52

Directors' Talk PODD 2025 - Keynotes & Key Themes

53

Enhanced Strategic FDA Collaboration: Working with CDER and CBER

54

Biomaterial Implants to Reduce Patient Burden and Improve Adherence

55

Are Site Networks the Solution to the Industry Productivity and Recruitment Challenge?

56

2025 Biotech Markets & Immuno-Oncology Outlook

57

Directors' Talk DPHARM 2025 - Pharma from the Trenches; Part II

58

Directors' Talk DPHARM 2025 - Keynotes & Key Topics; Part I

59

Streamlining Effective Patient Engagement through Pharma-Patient Advocacy Collaboration

60

Lessons Learned in the Development and Introduction of Closed Loop Systems

61

Best Practices and Potential Pitfalls Enriching Clinical Trials with PROs

62

Operationalizing the Patient Voice for Long-Term Protocol Planning and Execution

63

Navigating Data Quality and Scalability Challenges when Using Real-World Data from EHRs

64

Addressing the Realities of Scaling T-Cell Therapies for Patient Access and Affordability

65

The Current Status of Patient Centricity in Medicine Development

66

Patients as Partners Caregiver Keynote - The Life-Changing Power of a Clinical Trial

67

Bispecific Antibodies for PD-1 and VEGF: Impact and Market Dynamics for IO Landscape

68

Sustained Release Innovations to Reduce Patient Burden

69

How Pharma Is Adopting Generative AI Across Clinical Development

70

Tufts Center for Study of Drug Development on Evolving Clinical Trial Partnerships

71

New Approaches to Achieve Targeted Brain Delivery Without Increasing Toxicity

72

Partnering with Patients in Clinical Development Using the Biopsychosocial Model

73

Vaccine Delivery Innovations

74

How PALADIN Consortium Aims to Enhance Efficient Patient Advocacy-Industry Collaborations

75

What CMOs Need to Know and Do When Preparing for Product Launch

76

What to Expect at the 2025 Patients as Partners EU Conference

77

Understanding Financial Barriers to Getting More Coverage for Patients in Clinical Trials

78

How Montefiore Gets Early Stage Clinical Trials to Under-Resourced Communities

79

Investment Trends in Immuno-Oncology

80

Advances in Pulmonary Delivery of Biologics

81

Strategies for CMOs to Scale Up Effectively as Their Biotech Company Evolves

82

Boehringer Ingelheim on Collaborations in Clinical Development for Launch Readiness

83

Payer Perspectives on Drug Delivery

84

Patient Engagement: Practical Approaches for Emerging Biotech CMOs

85

Immuno-Oncology Debate 2024 on Solving Cancer’s Top Challenges

86

CMO Misunderstandings about Clinical Operations and How to Improve

87

How Roche is Maximizing the Impact of Patient Insights in Early Development

88

Designing and Developing Drug Delivery for Lower and Middle-Income Countries

89

Making Clinical Research a Feasible Care Option Using Modern Software Infrastructure

90

Using Patient Insights Meaningfully throughout the Medicine & Disease Lifecycle

91

Innovative Approach for Elevating Patient-Centric Solutions in Pediatric Trials

92

Incorporating Quantitative Values of Patient Perspectives into Trial Design

93

Accessing a Novel Source of Patient Experience Data to Improve Clinical Research

94

Empathy and Behavioral Science in ePROs to Increase Data Collection Adherence

95

Antiviral Drug Development: Overcoming Challenges to the Current Model

96

Unlocking Pre-Enrollment Data to Help Sponsors Recruit and Enroll More Patients

97

Strategies to Empower Clinical Sites, Streamline Trials and Enhance Patient Care

98

The History of Tumor Vaccines, and Why the Newest RNA Cancer Vaccines Might Work

99

What Biotech CEOs Need to Know about Developing a Commercialization Roadmap

100

Simplicity in Technology Delivery for Clinical Trials

101

Micromachines, Biologic Approaches and New Tools Pushing the Boundaries in Oral

102

Combining AI and Empirical Science to Advance Cancer Immunotherapies

103

The Personal Impact of a Clinical Trial

104

The Future of Patient-Centricity: Advancing Frameworks to Achieve Greater Impact

105

Using AI to Accelerate the Next Generation of Oncology Immunotherapies

106

Immuno-Oncology Cell Therapy Data Analytics: What and How to Measure

107

What to Expect at CRAACO: Clinical Research as a Care Option 2024, in 5 Minutes

108

How to Enhance Clinical Trial Participation in Diverse Linguistic Backgrounds

109

Patient Engagement Advocate on Collaborating Successfully with Pharma

110

What to Expect at DPHARM 2024, with DPHARM Directors

111

Astellas Head of Patient Centricity on Patient-Centric Medicine Development

112

Preferences in Decentralization and Digitalization of Pediatric Clinical Trials

113

What CMOs Need to Know about Partnering with Hospitals & Clinical Research Sites

114

How CMOs Build a Network of Consultants

115

CMO Insights and Advice on Tailoring Your Pitch to Investors

116

Transitioning from Early Stage to Registrational/Pivotal Stage Development

117

Using Sustainability to Empower Patient Engagement Goals in Medicine Development

118

Discoveries from the Clinic that Help Inform IO Cell Therapy Moving Forward

119

Maximizing Regulatory Interactions

120

The CMO as a Translational Scientist

121

Optimizing the Integration of Mobile and Patient-Facing Tech in Clinical Trials

122

Delivering Exceptional Clinical Trial Experiences for Patients

123

ctDNA Potential for Prognostic Stratification, Tumor Insights & Drug Development

124

What to Expect at the 2024 Patients as Partners EU Conference

125

Taking Lessons from Manufacturing Immunotherapies to Accelerate Development

126

Enhancing Solubility with Novel Excipient Technologies

127

Measuring the Value of DCTs and Hybrid Models

128

Navigating and Adopting Innovation in a Post- Pandemic World

129

Turning a Search for Lung Cancer Biomarkers into a Patient Empowerment Community

130

Engaging All Stakeholders for Clinical Trial Patient Engagement and Value

131

Optimizing Medicine Development for Real-World Efficacy in Patients

132

How CMOs can Support the Overarching Process of a Fundraising

133

Prioritizing Development Programs that Align with Fundraising Catalysts

134

Interacting with Different Types of Investors as a CMO

135

Developing Internal and External Communication Strategies

136

What CMOs Need to Know About Medical Affairs

137

Achieving Targeted Delivery of Gene Editing Therapies

138

The Promise and Challenges of Ultrasound-Mediated Delivery

139

The Future of Digital Technology in the Connected Device Space

140

New Approaches in CNS/PNS Delivery

141

Precision Ophthalmic Delivery

142

Delivery Challenges from the Oncology Pipeline

143

Novel Nasal Products and Formulations

144

Overcoming Barriers to Adoption of Transdermal Delivery

145

Addressing the Clinical Operations Workforce Gap

146

Evolving US Clinical Trial Infrastructure for Better Trials & Emergency Response

147

Community Organization Perspectives on Improving Clinical Trial Initiatives

148

Patients on How R&D Organizations Can Better Operationalize Trials for Patients

149

Novartis’ Approach to Making Patients Feel Valued in Clinical Research

150

How Henry Ford Health Integrated Clinical Trials into Clinical Care

151

Reimbursement Challenges with Clinical Trials

152

Democratizing Access: Enabling All Care Locations to be Research Locations

153

Strategies for Building a Successful Clinical Research Team in the Care Setting

154

How to Optimize Inventory and Sample Management for Clinical Trial Health

155

Ensuring That Sites Are Set Up for Trial Success, Using Data and Technology

156

Innovating Patient Recruitment: A Conversation with BBK Worldwide Founders

157

10th Annual Mobile Tech in Clinical Trials: What to Expect in under 10 Minutes

158

CRAACO Director's Note Podcast on What to Expect in Under 6 Minutes

159

Current Challenges in Vaccine Delivery and Distribution

160

Providing the Right Level of Value to the Patient that Creates Value

161

Enhancing the Interferon Pathway to Attack Cancer

162

Innovative CRISPR-based Editing to Create Off-the-shelf Immune Cell Therapies

163

Investment Trends in IO

164

Investment and Collaboration Strategies in Cell and Gene Therapy

165

Mechanisms of Immune Evasion Mediated by Hypoxia- Inducible Factors

166

Neoadjuvant Immune Checkpoint Blockade: A Window into Treatment Response and Pri

167

Regeneron’s Approach to Strategic Collaborations, Licensing and Business Dev.

168

Panel: Targeted Radiotherapy and the Impact on IO

169

What’s Next on the IO Radar? Top 10 Recommendations from Dr Andrew Baum, Citi

170

KEYNOTE FIRESIDE CHAT with Dr Robert Langer and Dr Ester Caffarel-Salvador

171

Panel: Role of China in the BD Process

172

Gaining “Hard-to-Reach” Patients’ Input During the Global COVID Pandemic

173

How Janssen is Collaboratively Working with Patients and Sites to Advance DCTs

174

How Merck is Partnering with Communities to Support Clinical Research

175

Sanofi’s New Initiatives Firmly Embedding Patient Experience & Perspectives

176

Reflections on Alnylam and Conquering Delivery

177

Patient Involvement Legal Barriers to Be Aware of and Pathways to Overcome Them

178

Next Generation Immune Checkpoints: Deciphering Key Roles in the TME

179

Merck Reporting on Site Monitoring, Performance and Database Lock

180

The Role of RWD in the Development of Remdesivir

181

De-risking Combination Product Development Involving L Volume Sub Formulations

182

How Regeneron Got an FDA Approved Therapy for COVID in Record Time

183

Remote Monitoring to Improve Transitioning Home and Reducing Risk of Readmission

184

The Pfizer Pledge: Getting to 60% Remote Clinical Trials in 2022

185

Benchmarking Clinical Operations for Digital Maturity

186

Innovative Trial Designs to Reduce Patient, Site and Investigator Burden

187

Addressing the Lack of Structured, Clean Patient Data

188

Fireside Leadership Lessons: Driving Innovation to Support Patients and Sites

189

Why Rare Disease Therapeutics Need Early Market Access Planning

190

Effective Concentration for a Longer Period with Long Acting Injectables

191

Moderna on Innovating Clinical Trial Partnerships to Expand Access

192

Regeneron and Novartis on Innovating to Accommodate Growing Pipelines

193

Development of the Lipid Nanoparticles

194

Targeting TGF Beta in IO: Mechanisms, Challenges and Opportunities

195

Biomarkers in IO: Challenges and Putative Benefits of Multi-omics Technologies

196

Chair’s Opening Presentation with Barbara Lueckel Summary

197

A Decade After Checkpoints- What Do We Know, What Do We Need to Know and Getting

198

Achieving Diversity and Inclusion in Oncology Clinical Trials

199

How Long-Acting Implantables Are Taking Extended Drug Release to the Next Level

200

Advancements in CART for the Treatment of Glioblastoma

201

From Carer to Trailblazer: One Man’s Fight to Impact Clinical Research

202

Cell & Gene Therapy: Current Landscape, Lessons Learned and Paths Forward

203

What to Expect at the IO360° Summit in 6 Minutes

204

Solving for the Digital Divide: Building Trust with Mobile Tech for Patients

205

How Moderna Built a Digital Organization to Transform How Clinical Research Gets

206

Roche’s Industry Overview on the Drug Delivery Landscape 2022

207

Leveraging Mobile Technologies in the Development of Novel Digital Endpoints

208

How Mobile Tech is Enabling Smarter Trial Designs for Better Data and Access

209

FDA Update on Digital Health Technologies in Clinical Trials Draft Guidance

210

Taking Patient Involvement in Clinical Publications to New Heights

211

Partnering with Your Compliance Teams to Advance Meaningful Collaboration

212

What Statisticians Wish They Could Tell Their Chief Medical Officers

213

Tackling the Manufacturing Complexity of Complex to Deliver Pipelines

214

Misaligned Incentives: Physician Perspectives on the Integration of CRAACO

215

Rewriting the Way We Work Together to Integrate Clinical Care and Research

216

Volunteering for a Vaccine Trial, Tackling Racial Disparities in Healthcare

217

How Amgen is RISING Above with Clinical Trial Diversity

218

A Vision for the Integration of Clinical Research and Care

219

Addressing Barriers to Patient Community Access through Non-Profit Partnerships

220

Educating Patients and Non-Research Physicians on Navigating Clinical Research

221

Long Acting Injectables for Biologics

222

Where and How DCTs Can Truly Enable and Close the Gaps between Research and Care

223

Partnering with Health Systems to Enhance Diverse Patient Access in Trials

224

Novartis’ Approach to Patient Engagement

225

Workforce Planning & Reducing Churn to Support and Promote CRAACO

226

Guest Keynote Connecting Communities with the CEO of Etsy

227

Making Institutional Change to Offer Clinical Research Options in Health Systems

228

Microgravity to Develop Crystalline Monoclonal Antibodies for Subcutaneous

229

CMO-CEO Fireside Discussion on Working Through Challenges

230

Building Trust to Ensure Diversity, Equity, Inclusion in Clinical Research

231

Drug Delivery Pipeline and Technologies, a Year in Review

232

How Eli Lilly is Diversifying and Engaging Patients Using DCT Capabilities

233

Advice for Partnering Between Innovator Drug Delivery Companies and Big Pharma

234

Fighting to be a True Stakeholder in Clinical Care and the Impact on Diversity

235

The First 90 Days as a CMO

236

R&D Veteran on Leading a Biotech through Founding, IPO and Acquisition

237

Building up a Company Through to Commercialization and Beyond

238

Best Practices for Cross Functional Communication Strategies for the CMO

239

Nicholas Warne Drug Delivery Industry

240

Managing the Partnership Between Big and Small Pharma

241

Infusing Patient Perspectives Across All of Pfizer

242

The Changing Environment Around Accelerated Approvals and Regulatory Pathways

243

Positioning Yourself For Board Roles and What to Expect as a CMO in Biotech

244

Biotech Financing Options and Their Implications

245

Building a Work Culture that Attracts and Retains Talent in Biotech

246

Exploring Ways to Reduce Costs of Developing & Manufacturing Drug Delivery Tech

247

Taking on the CMO Role at Moderna and Looking to the Future of Biotech R&D

248

What CMOs Must Know About How Patient Engagement Supports the Entire Biotech

249

Operationalizing the Integration of Patient Insights

250

How Sites Using Their Own Technology for Research Benefits All Stakeholders

251

Adjusting Your eCOA Strategy For Patient Centricity: Expert Advice

252

Sandoz's Chief Operating Officer Discusses the New Initiative Act4Biosimilars

253

A Natural Language Collaboration That Helps Cancer Patients Navigate Treatment

254

12th Annual DPHARM in Under 10 Minutes

255

Director's Notes on What to Expect at CRAACO: Clinical Research as a Care Option

256

What to Expect at Mobile Tech in Clinical Trials 2022

257

5 Minute Overview Podcast on What to Expect at PODD: Drug Delivery

258

Key Role of Strategy and Media in Improving Clinical Trial Enrollment Diversity

259

How CMOs Can Evaluate Potential Outsourcing Partners Effectively

260

Is the End of SDTM in Sight?

261

What Adapting During COVID-19 Taught Us About Innovating Drug Development

262

A Vision for the Future of Drug Delivery: Patients Interacting Less with Disease

263

How Listening Tech Disrupts Clinical Research to Create Patient-Centric Trials

264

On-the-Ground Perspective on Putting Decentralized Strategies in Clinical Trials

265

Biotech CEO Keynote, Dr Ron Cohen, from Chief Medical Officer Summit 360° 2021

266

R&D Veteran Keynote, Dr Jo Viney, from Chief Medical Officer Summit 360° 2021

267

10th Annual Chief Medical Officer Summit 360º in a Nutshell

268

The Case for Sites Using Their Own Tech to Accelerate Research and Reduce Burden

269

5 Talks to Watch (and Why) at IO360º 2022 with Strategic Advisor Dr Dan Chen

270

8th Annual Immuno-Oncology 360° Summit: What to Expect in 7 Minutes

271

Patients as Partners EU 2022 in 5 Minutes

272

How Artificial Intelligence Is Creating Better Clinical Trials, with Saama

273

Making the Leap from IV to Subcutaneous, with Halozyme's ENHANZE® Technology

274

J&J Vision on Progress in Eyecare and Meeting the Needs of Future Patients

275

Flexible Data Collection and Best DCT Strategies: Advice from an Expert

276

Building a Successful Relationship with your Development Partner

277

9th Annual Chief Medical Officer Summit 360° Overview in 5 Minutes

278

10 Year Review on Drug Delivery

279

8th annual Mobile in Clinical Trials in 5 Minutes

280

PODD 2021 in 7 Minutes with Director, Valerie Bowling

281

Ferring on Creating a First-in-Class Microbiome-Based Therapeutic

282

DPHARM in 10 Minutes with Director Valerie Bowling

283

The Biotech Incubator Helping Entrepreneurs Launch Companies to Advance Health

284

How and When to Pursue Decentralized Clinical Trials: Conversation with Experts

285

How to Utilize Technology to Truly Increase Diversity in Clinical Trials

286

Insights from CRAACO 2020 and Looking to the Future

287

The Practical Implementation of Sensors in the Changing Drug Development World

288

Patients as Partners Europe 2021 Overview in 5 Minutes

289

Innovations & Novel Approaches in IO Imaging & Assessing Responses

290

HLA Loss and the Impact on Immunotherapy

291

Cell & Gene Therapy Debate: Intrinsic Editing vs Systemic Combination

292

Operational Dynamics of Implementing & Managing Basket Trials

293

Overcoming Site Regulatory Issues to Optimize Clinical Quality

294

Evolution of Regulatory Policy For Cell/Gene Therapy

295

Centralized vs Decentralized Manufacturing

296

Next Generation Bispecifics in Solid Tumors

297

Ariella Chivil's Immunotherapy Trial Pathway

298

Insitu Vaccinations vs Systemic Neo-Epitope Vaccinations

299

What Do Next Generation of Immunotherapies Need to Look Like to Move the Needle?

300

Using Sensor Technology to Deploy Decentralized Trials and Improve Patient Care

301

Current Issues and Potential Solutions for Site Audit Readiness and Monitoring

302

5 Minute Overview of 8th Annual CMO Summit 360º

303

The Future of Clinical Research and the Innovation from the COVID-19 Pandemic

304

Connecting Care and Research for the Patient with a Decentralized Trial Model

305

Remote Monitoring for Clinical Research in the Digital Age

306

Solving for the Patient Retention Problem in Clinical Research

307

IO Combinations 360° Overview in 7 Minutes

308

Enabling Clinical Trial Continuity with Live Video Visits

309

Roche's Dr Barbara Lueckel's Opening Remarks and the 2018 Year in Review

310

How a Gene Therapy for Duchenne Muscular Dystrophy Came to Be

311

How a Covid-19 Research Study was Formed with Oracle, Javara and Wake Forest

312

IO Biomarker Discovery & Personalized Cancer Therapy Development with Personalis

313

The Impact of COVID-19 on Clinical Trials: Where are We? And Where are We Going?

314

7th Annual Mobile in Clinical Trials Overview in Under 5 Minutes

315

KPIs that Support Innovation for Patient-Engagement

316

Starbucks: Innovation for the End User Experience

317

Transparency and the Future of Patient Expectations

318

Turning Genes into Medicines: Gene Therapy for Genetic Disease

319

Formulation & Device Lifecycle Management for Biotherapeutics

320

Future Outlook for Novel Drug Delivery

321

Modality Fluid Development: Evolving Pipelines and Drug Delivery Solutions

322

MedTech Fireside Chat: The Journey of an Emerging Medical Device Company

323

Case Study: Forming and Managing a Drug Delivery Alliance

324

Supporting Business Models for Scaled Connected Health Drug Delivery Products

325

Utilizing Digital Health Data to Improve Management, Prevention & Wellness

326

Understanding Jansen's Metaphyseal Chondrodysplasia

327

The Collective Struggle to Evolve Data and Analytics Culture & Capabilities

328

Re-Thinking Clinical Development - Using Historical Data to Transform Trials

329

The Evolution of Using Real World Data to Create Trial Readiness Cohorts

330

The PD-FIDI: Developing a Digital Endpoint for Parkinson's Disease

331

Planning For and Addressing Missing Data in Mobile Clinical Trials

332

Balancing Innovation with Solid Common Sense to Deliver Innovative Medicines

333

Virtual Trials: What are We Striving for and Measurements of Success

334

Escaping Pilotville: How to Scale Mobile / Digital Deployment in Clinical Trials

335

Merck's Strategy to Mobilize Mobile Efforts and Engineer for Scale

336

What Does a Successful Digital Trial Look Like?

337

Advocating for People Managing Hermansky-Pudlak Syndrome

338

Maintaining Clinical Trial Patient Engagement in COVID with Be the Partner

339

Setting Up Therapeutic + Vaccine Programs for COVID-19: Lessons Learned

340

Understanding Spinal Muscular Atrophy: A Chief Scientific Officer's Perspective

341

Changing How We Treat Systemic Sclerosis

342

New Opportunities for Cell Therapy Combinations

343

PD1 Resistance with a Multi-Omic Approach

344

Updates on PARP Inhibition

345

Leveraging the Tumor Microenvironment for IO Therapy

346

Updates on Bintrafusp alfa/M7824 Clinical Data

347

NKTR-214: Harnessing the IL-2 Pathway in Combination Immunotherapies

348

Advancing Bispecifics for Combination Immunotherapy

349

How AI, Machine Learning and Big Data are Used to Inform Combinations

350

Weighing Your Options in Considering Clinical Trials from a Patient Perspective

351

Understanding the Goals of Care vs Research

352

6 Min Podcast on What to Expect at the 7th Annual Patients as Partners

353

How to Integrate Industry Sponsored Clinical Trials Into Your Health System

354

How Sanford Health Systems Increased Clinical Trial Participation to 10%

355

Keynote: Surgeon’s Perspective on Integrating Clinical Care & Clinical Research

356

How Wilmington Health is Streamlining Integration of Clinical Research & Care

357

Addressing Barriers Health Systems Face in Integrating Clinical Care & Research

358

Effectively Democratizing Access to Clinical Trials for All

359

Delivering an Innovative, Patient-Centric Delivery System

360

Ophthalmology: Exploring Other Routes of Administration

361

Transforming Cardiovascular Treatment with Pulmonary Delivery

362

MRI-Guided Focused Ultrasound and the Delivery of Therapeutics to the Brain

363

Better Strategies to Inform Patients on Clinical Research & Trial Participation

364

Chief Patient Advocate/Officer: Driving Culture Change from the Top Down

365

How Novartis Includes Patient Input into All Aspects of a Clinical Study

366

Patients as Partners in Clinical Research EU 5 Min Upcoming Conf Summary

367

Partnering with Patients on Clinical Development Protocols

368

Improving Clinical Research and Trials Through Pharma/Advocacy Partnerships

369

Engaging with Communities to Educate and Enroll Diverse Populations

370

Mapping Out the Patient Decision Journey

371

FDA Patient Engagement Synergistic Efforts

372

The Democratization of Patient Data Ownership: Returning Results

373

Cell & Gene Therapy Day Overview in 4 minutes

374

2020 Immuno-Oncology 360° Summit Overview in 10 Minutes

375

Fireside Chat with an R&D Veteran

376

Designing Clinical Trials for Gene Therapy - A Paradigm Shift

377

Case Study: Life of a Chief Medical Officer Pre and Post IPO

378

How the CMO of Sage Therapeutics Positioned a New Indication for FDA Approval

379

Addressing the Talent Gap in Biotech - Recruit and Retain

380

How to Navigate the Development Path from CMO to CEO

381

How do Patients Become Partners in the Sharing of Data to Advance Science?

382

Best Practices for Pharma - Patient Advocacy Partnerships

383

Merck's Next Phase of Patient Centricity in R&D

384

Clinical update on AMG 420, an anti-BCMA BiTE®

385

Connecting Employee-Centric Culture to Patient-Centric Culture

386

Eliciting Patient Experience Data to Understand Medicines Benefits/Disadvantages

387

Understanding the Language of Patients - The Value of Health Literacy

388

UCB and Parkinson's UK Collaboration Improve a Trial through Patient Involvement

389

Improving T Cell Therapies via Next Generation Technologies

390

Monetizing Science: Turning an Asset into Value through IPOs

391

IDO Changes the T-cell Balance in the Tumor Microenvironment

392

Insights from Deal Trends: Betting on Tumor Immunology

393

Living with Alzheimer’s from a Young Patient's Perspective

394

Organizational and Digital Restructuring to Scale Mobile Clinical Trials

395

How to Align the Promise of Technology with the Patient Voice

396

The Role of Digital Biomarkers and the Impact on Drug Delivery

397

PODD: Partnership Opportunities in Drug Delivery 2019 Overview in 4 Minutes

398

A Patient Perspective on Living with Parkinson's Disease and the GDNF Trial

399

The Future of Mobile Data in Clinical Trials: Challenges and Opportunities

400

Eli Lilly: How to Launch Multiple Mobile Devices in a Hybrid Setting

401

Pfizer’s Atopic Dermatitis Clinical Trial with Digital Wearable Technology

402

Merck’s Digital Health and Al Strategy: Progress Report

403

How Digital Biomarker Innovation is Modernizing Clinical Endpoints

404

Regenerative Medicine as a Disrupter in Clinical Trials

405

6th Annual Mobile in Clinical Trials: What to Expect in 4 Minutes

406

Estonia, The Digital Republic: Where Patients Own Their Data

407

Co-Creating the Industry's Scalable Solution for EHR

408

Bringing Blockchain to Life: Digitizing Clinical Supply Chain in Trials

409

Bayer: Virtual Assistants for Sites and Patients in Clinical Trials

410

DPharm: Disruptive Innovations in Clinical Trials 2019 Overview in 5 Minutes

411

Entrepreneur Data Scientist, Ben Liu on Solving Bottlenecks in Clinical Research

412

Stories from Bioinspiration to Innovation

413

Including Wellness in the Pharma Model - How Drug Delivery will be a Key Enabler

414

Service & Patients in Clinical Trials

415

Panel: Delivering mRNA Drugs and Vaccines – Progress and Future Outlook

416

How to Innovate like Amazon to Modernize Clinical Trials

417

Alzheimer’s Studies: Exploring Registries to Improve Enrollment & Trial Design

418

4th Annual IO Combinations 360°: What to Expect in 8 Minutes

419

CAR-T Therapy: Optimization Through Engineering T-cells or Combinations

420

Combining IO Modalities In a Cost Effective, Patient Beneficial Manner

421

IO Partnering Strategies In an Increasingly Complex Environment

422

Next Generation Biomarker and Companion Diagnostics for Predicting Response

423

Innovations in Immuno-Oncology Imaging

424

2nd Annual Drug Delivery West - 5 Minute Overview

425

Modernizing Clinical Trials with IQVIA's Dr Cynthia Verst

426

Integrating Care and Research with Dr Laura Esserman

427

Drug Delivery Global Health Challenge

428

Patient Perspectives on Drug Delivery Needs Present and Future

429

What are the Regulatory and Ethical Concerns of Integrating Care and Research?

430

How Can We Work with Medical Practices to Offer Patients Clinical Trials?

431

Why Are Clinical Trials Not Typically a Care Option?

432

How to Move Clinical Research into Communities That Would Truly Benefit

433

Lessons Learned from a Veteran Biotech and Investor MD

434

Case Study: Preparing for the Challenges of Late Stage Trials

435

Should Patients Have the Right to Try?

436

Best Practices in Communication and PR Strategy

437

Translating Patient Insight and Patient Experience Internally into Deliverables

438

Progress and Future Outlook of Cancer Immunotherapy

439

Panel: Engaging Patients By Giving Them their Data

440

Mobile Technology in Clinical Trials: Clinical Trials Transformation Initiative

441

How GSK Implemented Pivotal End-to-End Engagement Initiatives at Different Stage

442

How to Make Patient Involvement Sustainable Throughout Medicines Development

443

What Does a Truly Patient-Centered Healthcare System Look Like in 5-10 Years?

444

6th Annual Patients as Partners US: What to Expect in 8 Minutes

445

How Partnering with Medical Research Charities is Key to Medicines Development

446

Patients as Partners Europe 3rd Annual What to Expect in 5 Minutes

447

How Tesaro is Integrating the Patient in the Clinical Development Process

448

Keytruda in Combo with Chemo in NSCLC

449

Future Value Generation in Immuno-Oncology

450

Reflections of the Cancer Moonshot and Future of the Biden Cancer Initiative

451

Balancing Benefit and Toxicity from Immunotherapeutics

452

The BioCentury Report on Immuno-Oncology Industry Trends

453

5th Annual Immuno-Oncology 360˚: 12 minutes of What to Expect

454

Partnership Opportunities in Drug Delivery 2018: What to Expect 5 Min Podcast

455

Podcast: From a Zimbabwean Village Kid to a PhD Regenerative Medicine Student

456

All of Us Research Program, a Nation-wide Initiative from the NIH

457

Reimagining Clinical Trials with Entrepreneur, Dr Ben Liu, CEO, Trialspark

458

Blockchain Opportunities for Patient Data Donation and Clinical Research

459

DPharm Podcast: What to Expect at the 2018 Event in 8 Minutes

460

Mobile in Clinical Trials Podcast: 3 1/2 Minutes on What to Expect

461

What to Expect at Rational Combinations 360° 2018 - 5 Min Overview

462

How to Innovate in the Drug Delivery Space

463

Key Trends in Drug Delivery: Expert Perspective

464

How FARA and Horizon Pharma Partnered to Improve Clinical Development

465

How Takeda Used One or More of the Various Patient Engagement Frameworks

466

How Patient Research Advocates are Driving R&D: A Patient Case Study

467

Fireside Chat: Lessons Learned from a Drug Delivery Pioneer and Risk-Taker

468

Nanotechnology Keynote

469

Utilizing a Device Platform Technology across Multiple Therapeutic Categories

470

CEO Keynote Fireside Chat

471

Addressing R&D Challenges using Drug Delivery Technologies

472

Panel: Hitting the "Reset" Button on Direct-to-CNS Delivery

473

Current and Emerging Drug Delivery Needs in Oncology

474

Building Blocks of IO Clinical Trials - Part 2

475

Building Blocks of IO Clinical Trials - Part 1

476

Endpoints News Industry Report on IO Collaborations and Trends

477

CTTI Report - Mobile Clinical Trials Program: Recommendations on Novel Endpoints

478

How a Mobile App Can Offer Unique Value in Assessing Patient Reported Outcomes

479

Lessons Learned from the Journey of a CMO Leader, Michael Rosenblatt, MD

480

Developing a Pathway for Compassionate Use Cases

481

2018 Chief Medical Officer Summit Podcast Overview in a Nutshell

482

Clinical Research as a Care Option, 2nd annual - 3 min Podcast Overview

483

What to Expect at Clinical Trial Collaborations 2018 – 5 min Podcast

484

Mobile in Clinical Trials Europe New for 2018 - 4 min Podcast Overview

485

Patients, a Seat at the Table in Clinical Trials with Pfizer’s Dr Roz Schneider

486

Reducing the Burden of Type 1 Diabetes with Patient Dana Lewis:DPharm Podcast #5

487

5th Annual Patients as Partners What to Expect Overview Podcast in 7 Minutes

488

Wireless Remote Monitoring – DPharm Podcast Series #2

489

Immuno-Oncology Clinical Trial Operations 4 Min Summary of What to Expect

490

Patients as Partners EU Overview in 3 Minutes

491

Roche's Dr Barbara Lueckel Reviews the 2016 Drug Delivery Industry

492

From the Olympics to Clinical Research

493

What to Expect at Immuno-Oncology 360° 2018

494

Why Pharma R&D has to Start Thinking Like a Service Industry and How?

495

The Gap Between Clinical Care, Patient Involvement & What Patients Want

496

Digital Solutions Impacting the Economic Efficacy of Clinical Trials

497

Partnering with Patient Organizations for Advancing Cures

498

Challenges and Opportunities in Pursuing a New Therapeutic Modality

499

Partnering with Patients in the Development and Lifecycle of Medicines

500

Trends and Collaborations in the IO Space

501

Unlocking the Power of Patient Engagement within Clinical and Commercial

502

Patients Influencing Policy in the EU

503

Immuno-Oncology 360°: Business Models for Complex Science by Dr Axel Hoos of GSK

504

Increasingly Critical Role of Predictive Biomarkers in Cancer Immunotherapy

505

Important Business Aspects of Immuno-Oncology: Issues and Controversies

506

Innovative Ways of Patient Involvement in Medicines Development

507

Addressing Clinical Challenges in Immuno-Oncology

508

Sequencing of Combination Agents in Immuno-Oncology with Dr Charles Drake

509

Next Generation of Combination Immunotherapy with Dr Patrick Hwu of MD Anderson

510

Patients as Partners Europe 7 Minute Overview on What to Expect?

511

5 Minute Overview of DPharm (Disrupting Clinical Trials) Europe: What to Expect?

512

Immuno-Oncology 360 Conference in 5 Minutes: What to Expect?

513

DPharm Team Discuss 2016 Highlights

514

Pfizer's Blue Sky Approach to Help Transform Clinical Research

515

Communicating the Good, Bad & Ugly for CMOs and R&D Leaders in Biotech

516

Clinical Trial Opportunities in Puerto Rico

517

Alternative Model to Transform a Funding Gap in Rare Disease Clinical Research

518

A New Economic Solution to Drive Cures to Patients

519

Partnering with Patients in the Development & Lifecycle of Medicines

520

Immuno-Oncology Drug Development: Challenges & Next Steps

521

Making Clinical Trials a Care Option for Patients: Piloting an Infrastructure

522

Safety Elements of Cancer Immunotherapies: Immune Related Adverse Events

523

How the Availability of Capital Impacts the Role of the CMO

524

How Investors Assess R&D Biotech Management

525

The Journey of a Physician CEO with David Schenkein, MD, CEO, Agios

526

Clinical Air Episode #14 Consumer Electronics in Clinical Research

527

Immuno-Oncology: Exploring the Challenges & Potential

528

Design Thinking for Clinical Trials

529

Clinical Air Episode #13 Transcelerate & Industry Engagement

530

Risk Based Monitoring: New Thinking on Clinical Oversight

531

Clinical Air Episode # 12: Digital Startups & Applications for Clinical Research

532

Clinical Air Episode #11: How can Digital Complement and Disrupt Clinical Trials

533

Clinical Air Episode # 10 Patients as Partners in Clinical Trials

534

Clinical Air Episode # 9 Investing in the Future of Clinical Research

535

Clinical Air Episode # 8: Investigators as Partners in Clinical Research

536

Clinical Air Episode # 7: Engaging Patients by Sharing Electronic Clinical Data

537

Clinical Air #6 Clinical Trial Visits of the Future

538

Barriers and Limitations in Engaging Patients in Clinical Trials

539

Clinical Air Episode #5 Applications for Mobile/Sensors in Clinical Research

540

Clinical Air Episode #4 Clinical Innovation Continuum

541

Clinical Air Episode #3 Dpharm & Beyond

542

Clinical Air Episode #2:To Serve Patients in Clinical Trials

543

Managing the Role of Chief Medical Officer in a Biotech

544

Navigating the Complexities of Global Clinical Trials

545

Clinical Air Episode #1: Clinical Trial Calling